Rakhee Rajan Vaidya, MBBS

Rakhee Vaidya practices at Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina.

Rakhee Vaidya's NPI, 1962735167, was assigned on September 8, 2009. Rakhee Vaidya holds North Carolina license 2014-01855.

Rakhee Vaidya's primary practice is Davie Surgery - Ophthalmology - HOPD, at 329 Nc Highway 801 N, Bermuda Run, NC 27006.

Rakhee Vaidya's primary practice is Davie Surgery - Ophthalmology - HOPD in Bermuda Run, North Carolina. Rakhee Vaidya is also affiliated with Atrium Health Wake Forest Baptist Medical Center. The medical group on file is Atrium Health Wake Forest Baptist.

Dmand AI tracks the electronic health record (EHR) system at each site where Rakhee Vaidya practices, 2 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Rakhee Vaidya's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Rakhee Vaidya's licenses on file in 2 states: North Carolina and Minnesota.

CMS data shows 202 Medicare services from Rakhee Vaidya across 2 procedure codes in 2024, for 120 Medicare patients. Medicare paid $13,046 for them.

CMS counts 120 Medicare patients who saw Rakhee Vaidya in 2024. The largest group is 65 to 74, with 54 patients. 75% of them have high blood pressure, and 75% have high cholesterol. Their average risk score is 2.48, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Rakhee Vaidya's median patient age at 73, with 42% women.

In 2024, Rakhee Vaidya wrote 388 Medicare Part D claims for 94 patients. 68% of them were for generic drugs. CMS names the drug for 211 of them, across 11 drugs with 11 or more claims each, at $1,052,658 in total drug cost. In 2023, CMS named 203 claims across 11 drugs.

Rakhee Vaidya accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Rakhee Vaidya as offering telehealth.

CMS Open Payments shows 11 general payments to Rakhee Vaidya from 8 drug and device companies from 2016 to 2025. Speaker and faculty fees make up the largest share, 82% of the total. Celgene Corporation paid the most, $1,594. It also lists 2 research payments totaling $1,345 in 2025.